First-in-human phase 1 dose escalation study of HX009, a novel recombinant humanized anti-PD-1 and CD47 bispecific antibody, in patients with advanced malignancies.

Citation

• Roohullah, A., Ganju, V., Zhang, F., Zhang, L., Yu, T., Wilkinson, K., . . . de Souza, P. (2021). First-in-human phase 1 dose escalation study of HX009, a novel recombinant humanized anti-PD-1 and CD47 bispecific antibody, in patients with advanced malignancies.. Journal of Clinical Oncology, 39(15_suppl), 2517. doi:10.1200/jco.2021.39.15_suppl.2517

Digital Object Identifier (doi)

• 10.1200/jco.2021.39.15_suppl.2517

Web Of Science Accession Number

Start Page

• 2517

End Page

• 2517

Volume

• 39

Issue

• 15_suppl

Place Of Publication

Abstract

UOW Authors

•   De Souza, Paul (external author)

Publication Date

• 2021

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Roohullah, A., Ganju, V., Zhang, F., Zhang, L., Yu, T., Wilkinson, K., . . . de Souza, P. (2021). First-in-human phase 1 dose escalation study of HX009, a novel recombinant humanized anti-PD-1 and CD47 bispecific antibody, in patients with advanced malignancies.. Journal of Clinical Oncology, 39(15_suppl), 2517. doi:10.1200/jco.2021.39.15_suppl.2517

Digital Object Identifier (doi)

• 10.1200/jco.2021.39.15_suppl.2517

Web Of Science Accession Number

Start Page

• 2517

End Page

• 2517

Volume

• 39

Issue

• 15_suppl

Place Of Publication